Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06432647 · ClinicalTrials.gov registry record · Phase 1

A SAD and MAD Study of the Safety, Tolerability, and Pharmacokinetics of ATH-1105

A Phase 1 study of Healthy Volunteers, sponsored by LeonaBio.

Completed
Registry status
Phase 1
Development phase
80
Enrollment target
1
Study location

NCT06432647 is a Phase 1 study of Healthy Volunteers that has completed, run by LeonaBio. The registered enrollment target is 80 participants, below the 481-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06432647, a Phase 1 study of Healthy Volunteers, has completed, sponsored by LeonaBio.

COMPLETED
Registry status
Phase 1
Development phase
80 participants
Enrollment target
1
Study location

Study Summary

The goal of this Phase 1 interventional study is to assess the safety, tolerability and pharmacokinetics of ATH-1105 in healthy male and female participants.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG ATH-1105

Study Locations (1)

Texas

  • Fortrea Clinical Research Unit Inc. - Dallas

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2024-04-24
Est. Completion 2024-11-25
Phase Phase 1

Sponsor

LeonaBio

8 total trials

What the Registry Record Tells You About NCT06432647

The ClinicalTrials.gov registry entry for NCT06432647 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 481-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (83% lower). The listed sponsor is LeonaBio, which has 8 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy Volunteers appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06432647 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT06432647 about?

NCT06432647 is a clinical study titled "A SAD and MAD Study of the Safety, Tolerability, and Pharmacokinetics of ATH-1105". The goal of this Phase 1 interventional study is to assess the safety, tolerability and pharmacokinetics of ATH-1105 in healthy male and female participants.

What is the current status of trial NCT06432647?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2024-04-24. Estimated completion is 2024-11-25.

What conditions does trial NCT06432647 study?

This clinical trial studies the following conditions: Healthy Volunteers.

What interventions are being tested in trial NCT06432647?

The interventions under investigation include: Placebo (DRUG), ATH-1105 (DRUG).

Who is sponsoring clinical trial NCT06432647?

This trial is sponsored by LeonaBio, which has 8 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06432647 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy Volunteers

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.